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1. Introduction 
Since 1970s several studies have shown a significant prevalence of cardiovascular disease 
(CVD) among patients with end-stage renal disease (Linder et al., 1974). Among patients 
treated by hemodialysis and peritoneal dialysis, the prevalence of CVD is approximately 
40%. Even after stratification by age, sex, race, and diabetes, CVD mortality in chronic 
kidney disease (CKD) patients is 10 to 20 times higher than in the general population (Foley 
et al., 1998). End-stage-renal-disease patients often have a high prevalence of cardiovascular 
risk factors as hypertension, diabetes and dyslipemia. Nevertheless, previous studies have 
shown that the high prevalence of CVD in hemodialysis patients is only partly explained by 
traditional risk factors (Cheung et al., 2000). Non-traditional risk factors have been emerged 
in the last decade. One of this non-traditional risk factor is C-reactive protein (CRP). 
In this chapter, it is tried to explain the results of several studies supporting an association 
between inflammation (measured by high levels of CRP), left-ventricular dysfunction and 
volume overload among patients with CKD and how volume overload, which is present at 
the very early stages of CKD, could be the main underlying factor contributing to the worse 
CV prognosis among these patients. 
2. Inflammation (C-reactive protein) in patients with chronic kidney disease: 
prevalence and prognostic factor 
CRP is considered the prototypical acute-phase reactant in man. Plasma CRP is produced by 
hepatocytes although other sites of local CRP synthesis have been suggested. 
The plasma half-life of CRP is about 19 hours and is constant under all conditions of health 
and disease, so that the sole determinant of circulating CRP concentration is the synthesis 
rate, which thus directly reflects the intensity of the pathological process stimulating CRP 
production. In most disease, the circulating value of CRP reflects ongoing inflammation 
and/or tissue damage much more accurately than other laboratory parameters of the acute-
phase response. The CRP concentration is thus a very useful nonspecific biochemical marker 
of inflammation, measurement of which contributes importantly to screening for organic 
disease, monitoring of the response to treatment of inflammation and infection and 
detection of intercurrent infection (Pepys et al., 2003). 
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Elevated CRP levels have been described in a significant proportion of end-stage-renal-
disease patients on hemodialysis or peritoneal dialysis (Arici et al., 2001). About one-third of 
patients with chronic renal failure have serum CRP concentration > 10 mg/l (Owen et al., 
1998). In healthy men, high CRP level has been identified as a risk factor for cardiovascular 
disease (Ridker et al., 2001). As occurs in the general population, prospective studies point 
to a correlation between CRP plasma levels and overall and cardio-vascular mortality also in 
end-stage-renal disease patients (Arici et al., 2001; Ikizler et al., 1999; Noh et al., 1998; Owen 
et al., 1998; Panichi et al., 2008; Wang et al., 2009; Yeun et al. 2000; Zimmermann et al., 1999). 
3. Inflammation and anemia 
In dialysis patients, inflammation expressed by high levels of CRP is also associated with 
low blood hemoglobin and/or resistance to eritropoyesis-stimulating agents (Barany et al., 
1997; Bradbury et al., 2009; Gunnel et al., 1999; Owen et al., 1998). This has been attributed to 
the inhibition of erythropoietin secretion by pro-inflammatory cytokines. Inflammation also 
contributes to anemia by inducing functional iron deficiency probably blocking the delivery 
of iron from the reticuloendothelial cells to the hemathopoietic cells. Cytokines may  
also induce ferritin synthesis directly or by increasing iron uptake into hepatocytes. The 
increase in ferritin synthesis by hepatocytes and reticuloendothelial cells underlies in the 
iron storage pool during inflammation. Thus, inflammation among patients with CKD can 
contribute to anemia and impaired response to erythropoietin. Erythropoietin resistance by 
itself has been associated with higher short-term mortality in CKD patients (López-Gómez 
et al., 2008). 
4. Inflammation and malnutrition 
High concentration of acute phase protein is correlated with low serum albumin in 
malnourished hemodialysis patients (Kaysen et al., 1997; Qureshi et al., 1998). Low serum 
albumin concentrations are highly associated with increased mortality risk in patients with 
renal replacement therapy (Lowrie et al., 1990). Hypoalbuminemia has been traditionally 
been assumed to result from inadequate protein and calorie intake. However, albumin is a 
negative acute-phase protein. The synthesis of this protein decreases during inflammation 
independently of nutritional state. Albumin concentration in dialysis patients is negatively 
correlated with levels of positive acute-phase protein. Moreover, inflammation and 
malnutrition data has been associated with the presence of atherosclerotic carotid plaques 
(Stenvinkel et al., 1999) describing the so called MIA (malnutrition-inflammation-
atherosclerosis) syndrome in patients with advanced renal failure. 
In summary, inflammation is high prevalent among patients with chronic kidney disease 
and predicts anemia, malnutrition and CV death. An intriguing question is whether CRP is 
just a sensitive marker of systemic inflammation or actively contributes to the development 
and progression of atherosclerotic lesions and, therefore, to the CV damage. Some authors 
have demonstrated CRP content inside the atherosclerotic lesions, suggesting the active 
participation in the inflammatory process (Zhang et al., 1999) what hints that inflammation 
could be the cause rather than the consequence of CV damage. Based on the bad prognosis 
of patients with markers of inflammation, it is important to try to known the possible causes 
of inflammation in this population in order to prevent morbidity and mortality. 
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5. Possible causes of inflammation  
The causes of inflammation in patients with CKD patients remained unclear over time.  
Several studies have attempted to address the question as to whether some factors related to 
the dialysis technique by itself could induce the inflammatory response. Activation of 
monocytes with the subsequent enhanced release of inflammatory cytokines can be caused 
by membrane-induced complement activation, by direct cell-membrane interaction and by 
dialysis fluids containing endotoxins (Carracedo et al., 2006; Honkanen et al., 1991; Kerr et 
al., 2007; Schouten et al. 2000).  
However, a similar prevalence of inflammation has been described in patients with 
advanced renal failure not yet on dialysis (Ortega et al., 2002; Panichi et al., 2002; Stenvinkel 
et al., 1999). An inverse correlation between CRP levels and clearance of creatinine has been 
observed (Panichi et al., 2002); thus, CRP levels increase as renal function declines. This 
finding suggests the possibility of a decreased renal clearance of CRP as a cause of an 
activated acute-phase response in patients with chronic kidney disease. Another possibility 
could be that uremia by itself could be the cause of inflammation among these patients. 
However, in another study performed in pre-dialysis patients with a more homogeneous 
clearance of creatinine   (Ortega et al., 2002), a non-normal distribution of CRP levels were 
detected. That means that only a group of patients with advanced renal failure shows high 
levels of CRP, whereas other patients with the same degree of renal insufficiency have even 
normal CRP values. Hence, it seems that uremia by itself is not the unique cause of 
inflammation. Probably, inflammation could be related to some factors, frequently 
associated with renal failure, which can worsen with the worsening of renal function. In this 
study (Ortega et al., 2002), CRP levels were higher in those patients with a previous history 
of CVD. Comparing with patients with normal CRP levels at baseline, patients with higher 
levels maintained significant higher levels on follow-up. This group of inflamed patients 
showed during the study period persistently lower serum albumin, lower blood 
hemoglobin, needed higher doses of erythropoietin stimulating agents and showed higher 
hospitalization rate (table 1). 
 
 Group I 
(CRP>6 mg/dL) 
n = 23 
Group II 
(CRP<6 mg/dL) 
n = 43 
P value 
CRP (mg/L)* 21.6 (12.9 - 32.6) 2 (2 - 4.6) 0.00001 
Albumin (g/dL) 3.5 ± 0.4 3.8 ± 0.4 0.017 
Hemoglobin (g/dL) 11.6 ± 1.1 12.2 ± 0.8 0.045 
Epo (IU/kg/week) 67 ± 32 43 ± 20 0.025 
Hemoglobin/Epo 0.19 ± 0.08 0.32 ± 0.13 0.004 
Hospitalization (n) 0.52 ± 0.8 0.03 ± 0.19 0.004 
Table 1. Comparison of the evolution of analytical and clinical data between patients with 
high (Group I) or low (Group II) CRP levels at baseline. Mean ± standard deviation. 
*Median (interquartile range). 
In summary, at this point we know  that inflammation is high prevalent among patients 
with CKD, that the prevalence is higher among patients with associated CVD, that 
inflammation tends to increase with the decline of renal function but that only about one 
third of patients with advance renal function shows persistently high levels of inflammatory 
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markers. Thus, we could argue that uremia by itself is not the cause of inflammation. It 
seems that another factor, usually associated with uremia and which usually worsens with 
the decline of renal function could be the responsible of inflammation in patients with CKD. 
In the past decade, it has been observed that circulating inflammatory cytokines are elevated 
in patients with chronic heart failure (Levin et al., 1990) and it has been suggested that 
cytokines can be in part responsible for cardiac disease progression in these patients (Seta et 
al., 1996). Some authors have detected elevated plasma levels of endotoxins and cytokines 
during the acute phase of heart failure and that normalization of endotoxins and cytokines 
concentration can be achieved using intensive diuretic treatment (Niebauer et al. 1999, 
Peschel et al. 2003). The authors hypothesized that during acute cardiac decompensation, 
acute mesenteric venous congestion with subsequently altered gut permeability for 
endotoxins would lead to translocation of these materials into the circulation inducing the 
inflammatory response. Thus, the authors highlight that inflammation could be the 
consequence, rather than the cause of heart failure. 
6. Association between inflammation, overhydratacion and cardiac disease: 
B-type natriuretic peptide 
Cardiac disease is high prevalent among patients with CKD (Foley et al. ,1995; Hayashi et 
al., 2006; Levin et al., 1996; Zocali et al., 2004). The typical feature of uremic cardiomyopathy 
is left ventricular diastolic dysfunction related to left ventricular hypertrophy and left 
ventricular fibrosis (Ahmed et al., 2007; Losi et al., 2010; Mark et al., 2006). Left ventricular 
hypertrophy is particularly highly prevalent in end-stage renal disease patients because of 
hypertension, hyperparathyroidism and increased volume. However, myocardial fibrosis is 
a specific finding among patients with CKD comparing with patients with isolated 
hypertension as revealed autopsy studies (Sharer et al., 1999). Probably, volume overload 
could be a main cause of myocardial fibrosis among these patients as volume overload can 
produce mechanical stress on the ventricular wall and it has been demonstrated that 
mechanical factors can induce the activation of the fibroblasts of the myocardium 
synthesizing the extracellular matrix (MacKenna et al., 2000). Volume overload is present 
very early in the course of CKD and is the consequence of the inability of the insufficient 
kidney to eliminate the excess of water and salt. Usually, the increase in extracellular water 
in the very early course of CKD is modest and may easily be underestimated by clinical 
examination and can only be proved by accurate measurement of body water volume, as 
with bioimpedance. Extracellular water excess increases when glomerular filtration rate 
declines and has emerged as an independent factor in the structural cardiac damage, as  a 
direct relation between extracellular water excess and left ventricular mass has been 
demonstrated as well as with left ventricular data of diastolic dysfunction (Essig et al., 2008). 
The authors also highlighted that cardiac remodeling was present at the very early stages of 
CKD. Over time, structural myocardial alterations progress, leading to diastolic dysfunction. 
The central disturbance in diastolic dysfunction involves abnormalities in myocardial 
relaxation and ventricular compliance (Martos et al., 2007). Thus, in order to complete 
ventricular filling and achieve a sufficient end-diastolic volume, which will provide 
adequate stroke volume, the left ventricle needs filling pressure higher than normal. 
Diastolic dysfunction, in fact, means that the left ventricle fills at higher pressure. 
Echocardiographic data of diastolic dysfunction are the most frequent findings among 
patients with CKD (Hayashy et al., 2006). 
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Based on the association between inflammation and heart failure in the general population 
and as myocardial dysfunction is high prevalent among patients with CKD, several authors 
tried to find an association between inflammation and cardiac disease also in this 
population. Furthermore, this hypothesis could explain why only some patients (those with 
more ventricular damage) show high levels of CRP, whereas other patients with similar 
clearance of creatinine (those with less cardiac disease) could present even normal values of 
CRP.  
Some authors (Ates et al., 2005; Kim et al., 2005) have observed an association between CRP 
and left ventricular hypertrophy or dysfunction among patients with CKD. However, most 
authors have employed in their studies the measurement of a biochemical marker of 
ventricular dysfunction such as B-type natriuretic peptide.  
B-type natriuretic peptide (BNP) is a cardiac neurohormone specifically secreted from 
cardiac ventricles in response to an increased left-ventricular wall tension (Maeda et al., 
1998). When end-diastolic filling pressure is increased (related to ventricular dysfunction, 
hypervolemia or both conditions), the release of BNP is induced. BNP is a potent natriuretic 
peptide by enhancing renal sodium excretion, reducing so the intravascular volume and, 
therefore, the end-diastolic volume and pressure. BNP is a strong predictor of systolic and 
diastolic abnormalities and is a powerful marker for prognosis and risk stratification in the 
setting of heart failure (Tabbibizar et al., 2002). In the general population, a cut point of 
about 100 pg/ml can discriminate patients with heart failure from patients without it.  
BNP is increased among patients with CKD and an inverse correlation between BNP levels 
and glomerular filtration rate has been observed (McCullough et al., 2003). This increased 
BNP level among these patients is in part related to the decreased renal clearance as well as 
the accompanying increased intravascular volume which is usually present in these 
patients. However, values above a cut-point reflect ventricular dysfunction and predict 
heart failure also among patients with CKD. In general, as CKD stage advances, a higher cut 
point of BNP is implied. BNP levels higher than 500 pg/ml usually predict heart failure 
even in patients with renal failure. Diastolic dysfunction is the most frequent cardiac disease 
among patients with CKD. In this setting, a small increment in end-diastolic volume lead to 
an exaggerated increase in diastolic pressure (Mandinov et al., 2000), inducing the release of 
natriuretic peptide. Probably, this pathophysiological mechanism partly explains the high 
levels of BNP detected among patients with CKD. In fact, several studies have observed an 
association between natriuretic peptide levels and echocardiographic data of left ventricular 
hypertrophy and dysfunction among patients with CKD (Guo et al., 2009; Paniagua et al., 
2010; Zocali et al., 2001). Natriuretic peptide levels among patients with CKD predict death, 
as it occurs in patients with heart failure and normal renal function. Otherwise, some 
authors (Jacobs  et al., 2010) have demonstrated a direct correlation between extracellular 
water, measured by bioelectrical impedance, and natriuretic peptide in CKD patients, 
explaining how volume overload can increase end-diastolic volume and, therefore, end-
diastolic pressure favoring the release of BNP. Probably both mechanisms, volume overload 
and myocardial damage, both high prevalent among patients with CKD, could explained 
the high levels of natriuretic peptides detected in this population. 
NT-proBNP is the amino-terminal peptide fragment of the precursor of BNP and shows a 
close correlation to BNP (Masson et al., 2002). A non-normal distribution of NT-proBNP 
levels was observed among patients with advanced renal failure, as previously observed 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
270 
with CRP (Ortega et al., 2004). Newly, it means that only a group of patients with advanced 
renal failure shows high levels of natriuretic peptides, whereas other patients with similar 
creatinine clearance show even normal values. This finding probably reflects the presence of 
a mixed population among patients with advanced CKD with a group of patients with more 
severe cardiac disease whereas other patients can achieve the end-stage disease phase with 
less myocardial damage. But most importantly, a strong correlation between NT-proBNP 
and CRP levels is found (figure 1), suggesting an association between left-ventricular filling 
pressure and inflammation among patients with CKD. 
 
 
 
 
Fig. 1. Regression graph demonstrating the correlation between NT-proBNP and C-reactive 
protein values at baseline (r: 0.7; p< 0.001) 
This association between left-ventricular filling pressure and inflammation among CKD 
patients has been confirmed in subsequent years (Guo et al., 2009; Jacobs et al., 2010; 
Paniagua et al., 2010). Otherwise, the same studies and other authors (Booth et al., 2010) 
observed a relationship between cardiac and inflammatory biomarkers and volume 
overload. An association between volume overload and inflammation had been previously 
observed among patients on peritoneal dialysis (Woodrow, 2006). Overhydration by itself 
has emerged as an independent predictor on mortality in chronic hemodialysis patients 
(Wizemann et al., 2009). 
Thus, all these findings show the complex relation between overhydration, malnutrition, 
inflammation and cardiac biomarkers in CKD patients. Although CRP can actively 
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participate in the atherosclerotic process inducing CV damage, it has also been suggested 
that inflammation among patients with CKD could be the consequence, rather than the 
cause, of an increased left-ventricular filling pressure, related to ventricular dysfunction, 
hypervolemia or both conditions (Ortega, 2005). 
The complex relation between ventricular dysfunction, overhydration and inflammation 
highlights the importance of strict volume control in patients with CKD. Usually, 
ventricular dysfunction progress over time. In an interesting longitudinal study performed 
in hemodialysis patients, a progressive deterioration of left ventricular filling pressure (an 
index of diastolic dysfunction) was observed in parallel with the progression of left 
ventricular hypertrophy and a progressive increment in levels of NT-proBNP (Kim et al., 
2011). Thus, these results suggest that diastolic dysfunction progress over time among 
patients with chronic kidney disease. In another longitudinal study performed in 
hemodialysis patients (Ortega et al., 2009), the effect of strict volume control on the 
evolution of cardiac biomarker levels over time was analyzed. In this study, the strategy of 
strict volume control permitted the stabilization of cardiac biomarker levels over time, 
suggesting that this strategy may prevent further progression of left ventricular 
hypertrophy, cardiac fibrosis and diastolic dysfunction. Patients with higher biomarker 
levels at baseline, probably those with more severe myocardial damage, were the most 
beneficed as NT-proBNP levels could even be reduced over time (figure 2). In these high 
risk patients, continuous prevention of fluid overload diminished the inflammatory 
parameters on follow-up, confirming the importance of volume control for preventing 
inflammation in dialysis patients (figure 3).  
 
 
 
 
Fig. 2. Evolution over time of NT-proBNP values among patients distributed in high quartile 
at baseline (NT-proBNP high) and those distributed in other basal quartiles (NT-proBNP). 
Data expressed as mean ± standard error. 
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Fig. 3. Evolution over time of CRP values among patients distributed in high quartile at 
baseline (CRP high) and those distributed in other basal quartiles (CRP). * p<0.05 vs baseline 
levels. Data expressed as mean ± standard error. 
7. Other cardiac biomarkers: Troponin T 
Cardiac troponins are regulatory proteins within the myocardium that are released into the 
circulation when damage to the cardiomyocite has occurred. Therefore, serum troponin is 
an exquisitely sensitive marker of myocardial injury during the acute coronary syndrome 
and is necessary for establishing the diagnosis of myocardial infarction (Daubert et al., 
2010). 
Cardiac troponins control the calcium-mediated interaction of actin and myosin, which 
results in contraction and relaxation of striated muscle. The troponin complex is made up to 
three subunits: troponin C, troponin I and troponin T. Troponin C is expressed by cells in 
both cardiac and skeletal muscle. In contrast, troponin I and T are unique to cardiac muscle. 
Among patients with acute coronary syndrome, cardiac troponin has not only diagnostic 
value, but yield prognostic information as well. It has been proven to be a potent 
independent indicator of recurrent ischemic events and an estimate for the risk of death 
among patients presenting with acute coronary syndrome (Heidenreich et al., 2001). 
Persistently elevated cardiac troponin is frequently observed among asymptomatic patients 
with end-stage-renal-disease and is associated with increased mortality (Apple et al., 2002; 
de Fillipi et al., 2003; Ogi et al., 2001). There has been proposed several mechanisms for 
explaining the high levels of troponin among patients with CKD. Although troponin is a 
relative large molecule which is believed to be cleared by the reticuloendothelial system, 
more recent evidence suggest that troponin T is fragmented into molecules small enough  to 
be renally excreted, which may partly explain the high prevalence of troponin T elevation in 
patients with renal failure (Diris et al., 2004). 
www.intechopen.com
Biomarkers in Chronic Kidney Disease -  
The Linkage Between Inflammation, Ventricular Dysfunction and Overhydration 
 
273 
Cardiac microinfarctions and arrhythmia have also been suggested as possible causes of 
elevations of troponin among patients with CKD. 
More recently,  it has been observed that CKD patients with high troponin T concentrations 
had clear evidence of myocardial dysfunction and raised left ventricular filling pressure  
(Sharma et al., 2006), supporting that volume and pressure overload can cause excessive 
ventricular wall tension with resultant myofibrillary damage or cardiomyocites death 
(Horwich TB et al., 2003). In this way, a strong association between troponin T and NT-
proBNP has been observed in hemodialysis patients (figure 4) (Ortega et al., 2009) and both 
troponin T and NT-proBNP levels has been observed to be higher in volume-overloaded 
CKD patients (Sommerer et al., 2007). 
 
 
 
 
Fig. 4. Regression graph demonstrating the correlation between NT-proBNP and troponin T 
values at baseline (r: 0.4; p= 0.002) 
Thus, it seems that the increased troponin T in a high proportion of patients with CKD could 
be related to myocardial injury induced by an increased left ventricular volume especially in 
those patients with diastolic dysfunction, in whom a small increase in end-diastolic volume 
produces an exaggerated increment in end-diastolic pressure with the subsequent 
myocardial damage. Furthermore, in hemodialysis patients, a strategy of strict volume 
control over time could significantly reduce the troponin T levels especially in those patients 
with higher biomarker levels at baseline, probably those with more severe myocardial 
dysfunction (figure 5) (Ortega et al., 2009). 
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Fig. 5. Evolution over time of troponin T values among patients distributed in the high 
quartile at baseline (Troponin T high) vs those distributed in the other basal quartiles 
(Troponin T). * p<0.05 vs baseline levels. Data expressed as mean ± standard error. 
8. Summary and future perspectives 
There is a complex association between ventricular dysfunction, cardiac biomarkers, 
malnutrition, inflammation and overhydration among patients with CKD, which could 
partly explain the high CV morbidity and mortality among these patients, comparing with 
the general population. 
Probably, these alterations begin in the very early stages of CKD and volume overload could 
be an important underlying factor. The inability of the insufficient kidney for excreting water 
and salt induces an increase in extracellular volume, which may be underestimated in the 
early phases of CKD. Persistently volume overload can induce an increment in blood pressure, 
myocardial hypertrophy and myocardial fibrosis. Over time, diastolic dysfunction develops. 
In this setting, further small increments in end-diastolic volume produce an exaggerated 
increment in end-diastolic pressure favoring the release of BNP and also, myocardial damage 
and cardiac remodeling. During cardiac remodeling, death of cardiomyocites is produced 
inducing a serum increment in troponins, and normal myocardium is progressively 
substituted by a fibrotic matrix, worsening so diastolic dysfunction. In this situation, systemic 
inflammation is produced by a yet non clear mechanism. 
Thus, in this chapter, it is  tried to highlight the importance of early intervention for 
controlling volume excess in the very early stages of CKD in order to prevent future cardiac 
dysfunction and inflammation, reducing so the bad CV prognosis of these patients. 
It is noteworthy that at this early stage of CKD some patients can show normal plasma 
creatinine, especially older patients or patients with low muscle mass, but they may be 
subclinically overhydrated. A prescription of low sodium diet and the carefully use of 
diuretics at this phase of CKD could be the main tool for preventing volume overload and 
future CV damage. 
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